<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;"><font style="font-weight: bold;">As filed with the Securities and Exchange Commission on October 8, 2024</font></div>
    <div><br>
    </div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div style="text-align: right; font-weight: bold;"> <br>
    </div>
  </div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="font-size: 14pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">UNITED STATES</div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      </div>
      <div>
        <div style="text-align: center;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
        </div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM S-8</div>
        <div>&#160;</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">REGISTRATION STATEMENT</div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">UNDER</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
      </div>
      <div>
        <div style="text-align: center;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div>
        <div>&#160;</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">ACASTI PHARMA INC.</div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
      </div>
      <div>
        <div style="text-align: center;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb29bdb8d37b74c33b19e14b6ef4dc31d">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>
                <div style="text-align: center; font-weight: bold;">Delaware</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>
                <div style="text-align: center; font-weight: bold;">98-1359336</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification Number)</div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3226e0903f064fd7875b1055a469252d">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">103 Carnegie Center, Suite 300</div>
              <div style="text-align: center; font-weight: bold;">Princeton, New Jersey</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div>
                <div style="text-align: center; font-weight: bold;">08540</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>
                <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>
                <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN</div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Full title of the plan)</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;">Prashant Kohli</div>
        <div style="text-align: center; font-weight: bold;">Chief Executive Officer</div>
        <div style="text-align: center; font-weight: bold;">
          <div style="color: #000000; font-weight: bold;">Acasti Pharma Inc.</div>
        </div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">103 Carnegie Center, Suite 300</div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Princeton, New Jersey 08540</div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0);">(Name and Address of Agent for Service)</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(609) 322-1602</div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0);">(Telephone Number, Including Area Code, of Agent For Service)</div>
      </div>
      <div>
        <div><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Copy to:</div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Steven J. Abrams</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Hogan Lovells US LLP</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">1735 Market Street, 23rd Floor</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Philadelphia, PA 19103</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">(267) 675-4600</div>
      <div>
        <div><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div style="text-indent: 36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
        accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze2350aceff30407788d873d410402a2c">

          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Large accelerated filer</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">&#9744;</td>
            <td style="width: 45%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Accelerated filer</div>
            </td>
            <td style="width: 4.57%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;"><br>
            </td>
            <td style="width: 35%; vertical-align: bottom;"><br>
            </td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 4.57%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Non-accelerated filer<br>
              </div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">&#9746;</td>
            <td style="width: 45%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Smaller reporting company</div>
            </td>
            <td style="width: 4.57%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">&#9746;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;"><br>
            </td>
            <td style="width: 35%; vertical-align: bottom;"><br>
            </td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 4.57%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;"><br>
            </td>
            <td style="width: 35%; vertical-align: bottom;"><br>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Emerging growth company</div>
            </td>
            <td style="width: 4.57%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">&#9744;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act.&#160; &#9744;</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">PART I</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Registration Statement (the &#8220;Registration Statement&#8221;) on Form S-8 is being filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) for the purpose of registering the offer and
        issuance of shares of common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) of Acasti Pharma Inc. (the &#8220;Registrant,&#8221; or the &#8220;Company&#8221;) to certain directors, employees and consultants of the Company and/or its subsidiaries under the
        Company&#8217;s 2024 Equity Incentive Plan (as it may be amended from time to time, the &#8220;2024 Equity Incentive Plan&#8221;).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Pursuant to Part I of Form S-8, the information specified under Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428
        under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to participants in the 2024 Equity
        Incentive Plan as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, when taken together, constitute a
        prospectus that meets the requirements of Section 10(a) of the Securities Act. Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as a prospectus or prospectus supplement
        pursuant to Rule 424 under the Securities Act.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">PART II</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc2a8d7e3600742acb306c1002ac2d77a">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Incorporation of Documents by Reference.</div>
            </td>
          </tr>

      </table>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">The following documents filed by the Company with the Commission are incorporated by reference herein:</div>
      </div>
      <div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z021c75e52787455984e26d66b8b2ce70">

            <tr>
              <td style="width: 27pt;">&#160;</td>
              <td style="width: 18pt; vertical-align: top;">(a)</td>
              <td style="width: auto; vertical-align: top;">
                <div>The Company&#8217;s Annual Report on Form 10-K for the year ended March 31, 2024, filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1444192/000095017024075875/acst-20240331.htm">June 21, 2024</a>;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="text-align: justify; text-indent: -45pt; margin-left: 45pt;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a7c7238d08b4e29914c01af8c5c26e5">

            <tr>
              <td style="width: 27pt;">&#160;</td>
              <td style="width: 18pt; vertical-align: top;">(b)</td>
              <td style="width: auto; vertical-align: top;">
                <div>The Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001444192/000095017024094348/acst-20240630.htm">August 9,
                    2024</a>;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="text-align: justify; text-indent: -45pt; margin-left: 45pt;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z560f743a4f3048d8a1ff66c03ad4bbec">

            <tr>
              <td style="width: 27pt;">&#160;</td>
              <td style="width: 18pt; vertical-align: top;">(c)</td>
              <td style="width: auto; vertical-align: top;">
                <div>
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; color: #000000;">The Company&#8217;s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports
                      that relate to such items), filed with the Commission on </font><a style="font-size: 10pt;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001444192/000095017024078447/acst-20240627.htm">June 27, 2024</a><font style="font-size: 10pt; color: #000000;">, </font><a style="font-size: 10pt;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001444192/000095017024098049/acst-20240812.htm">August 16, 2024</a><font style="font-size: 10pt;">,</font><font style="font-size: 10pt; color: #000000;">&#160;</font><a style="font-size: 10pt;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001444192/000114036124041832/ef20036277_8k.htm">September 25, 2024</a><font style="font-size: 10pt;">,
                      <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1444192/000114036124042352/ef20036442_8k.htm">September 30, 2024</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001444192/000114036124042968/ef20036564_8k.htm">October 7, 2024</a></font><font style="font-size: 10pt; color: #000000;">; and</font></div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="text-align: justify; text-indent: -45pt; margin-left: 45pt;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z566478002dc9455d821d11d2ff5f9034">

            <tr>
              <td style="width: 27pt;">&#160;</td>
              <td style="width: 18pt; vertical-align: top;">(d)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; font-size: 12pt;"><font style="font-size: 10pt; color: #000000;">The description of the Company&#8217;s common stock included in the final prospectus dated August 7, 2024, filed with the Commission on </font><font style="font-size: 10pt;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124036204/ny20029500x5_424b3.htm#tDOS">August 7, 2024</a><font style="color: rgb(0, 0, 0);"> pursuant to Rule 424(b)(3).</font></font></div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div><br>
        </div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the
        &#8220;Exchange Act&#8221;), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference
        herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are &#8220;furnished&#8221; rather than filed with the Commission; provided, however, that documents or portions thereof
        that are furnished and not filed in accordance with the rules of&#160; the Commission shall not be deemed to be incorporated by reference herein.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement
        contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so
        modified or superseded, to constitute a part hereof.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5b76f4da845a4a0f8162d5fcfbccf264">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 4.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Description of Securities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3db99ac902b44fe9859871e0a7907953">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 5.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Interests of Named Experts and Counsel.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3bee541abae94864bb145a9f5651da83">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 6.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Indemnification of Directors and Officers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Set forth below is a description of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), the Company&#8217;s Certificate of Incorporation and the Company&#8217;s Bylaws, as
        such provisions relate to the indemnification of the Company&#8217;s directors and officers. This description is intended only as a summary and is qualified in its entirety by reference to the DGCL, the Company&#8217;s Certificate of Incorporation and the
        Company&#8217;s Bylaws.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Section 102(b)(7) of the DGCL generally permits a Delaware corporation to provide in its certificate of incorporation that directors or certain officers of the corporation
        shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) with respect to directors and officers, any breach of the director&#8217;s or
        officer&#8217;s duty of loyalty to the corporation or its stockholders; (ii) with respect to directors and officers, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) with respect to
        directors, payments of unlawful dividends or unlawful stock repurchases or redemptions under Section 174 of the DGCL; (iv) with respect to directors and officers, any transaction from which the director or officer derived an improper personal
        benefit; or (v) with respect to officers, any action by or in the right of the corporation.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Section 145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any
        threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent
        of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and
        amounts paid in settlement actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner he or she reasonably believed was in or not opposed to the corporation&#8217;s best
        interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Section 145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any
        threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
        the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or
        settlement of such action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation&#8217;s best interests, except that no indemnification shall be permitted without judicial
        approval if a court has determined that the person is to be liable to the corporation with respect to such claim.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Section 145(c) of the DGCL provides that, if a present or former director or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the
        DGCL, the corporation must indemnify such officer or director against the expenses (including attorneys&#8217; fees) he or she actually and reasonably incurred in connection with such action.</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or
        agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any such
        capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability under Section 145 of the DGCL.</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">The Company&#8217;s Certificate of Incorporation contains provisions that limit the liability of the Company&#8217;s directors and officers for monetary damages to the fullest extent
          permitted by the DGCL. In addition, if the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Company&#8217;s directors and officers will be further limited to
          the greatest extent permitted by the DGCL.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">The Company&#8217;s Bylaws provide that the Company will indemnify its directors and officers, and may indemnify its employees, agents and any other persons, to the fullest extent
          permitted by the DGCL, subject to limited exceptions. The Company&#8217;s Bylaws also provide that the Company must advance expenses incurred by or on behalf of a current or former director or officer in advance of the final disposition of any action
          or proceeding, subject to limited exceptions.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Further, the Company has entered into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification
          provisions contained in the DGCL. These indemnification agreements require the Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These
          indemnification agreements also require the Company to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. The Company believes that
          these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.</div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;"> <br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Directors&#8217; and officers&#8217; liability insurance has been purchased for the benefit of the Company&#8217;s directors and officers to back up the Company&#8217;s indemnification of them
          against liability incurred in their capacity as directors and officers, subject to certain limitations under applicable law. The Company also maintains insurance policies under which its directors and officers are insured, within the limits and
          subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are parties by reason of being
          or having been directors or officers of the Company. The coverage provided by these policies may apply whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL.</div>
        <div><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfb185306f4b641cfb2db562caa6d9e99">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 7.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd9e0817232564f59bbf0c2f89fcbd61c">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 8.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z94f8c6be2e3748e3b68f6d6ee411fa9f">

          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; font-weight: bold;">Number</div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 91%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="font-weight: bold;">&#160;Description of Document</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124042968/ef20036564_ex3-3.htm">3.1</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>
                  <div style="color: #000000;">Certificate of Incorporation of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed with the Commission on October 7, 2024)</div>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124042968/ef20036564_ex3-4.htm">3.2</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>
                  <div style="color: #000000;">Bylaws of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K filed with the Commission on October 7, 2024)</div>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124042968/ef20036564_ex4-1.htm">4.1</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>
                  <div style="color: #000000;">Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Commission on October 7, 2024)</div>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="ef20036399_ex5-1.htm">5.1*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Opinion of Hogan Lovells US LLP</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124042352/ef20036442_8k.htm">10.1</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Commission on September 30, 2024)</div>
              </div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4bd387a1b13f44108f3f6ad5fb8c53a2">

          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124031597/ny20029500x1_ex10-3.htm">10.3</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Form of 2024 Incentive Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-4 filed with the Commission
                  on June 27, 2024)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="https://www.sec.gov/Archives/edgar/data/1444192/000114036124031597/ny20029500x1_ex10-4.htm">10.4</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Form of 2024 Non-Qualified Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-4 filed with the
                  Commission on June 27, 2024)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="ef20036399_ex23-1.htm">23.1*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Consent of KPMG LLP, independent registered public accounting firm</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="ef20036399_ex23-2.htm">23.2*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Consent of Ernst &amp; Young LLP, independent registered public accounting firm</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="ef20036399_ex5-1.htm">23.3*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Consent of Hogan Lovells US LLP (included in Exhibit 5.1)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="#POWEROFATTORNEY">24.1*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Power of Attorney (included on signature page hereto)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div><a href="exfilingfees.htm">107*</a></div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Filing Fee Table</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>*</div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 91%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>
                <div>Filed herewith</div>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e66dfa48fc1424fa794a030b01dfaf5">

          <tr>
            <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 9.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Undertakings.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned registrant hereby undertakes:</div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to the registration statement:</div>
      </div>
      <div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <div>
          <div style="margin-left: 72pt;"> (i)&#160;&#160;&#160; To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <div>
        <div>
          <div style="margin-left: 72pt;"> (ii)&#160;&#160;&#160; To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
            aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
            not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
            changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee Tables&#8221; or &#8220;Calculation of Registration Fee Table&#8221;, as applicable, in the effective
            registration statement;</div>
          <div> </div>
        </div>
        <div> <br>
        </div>
      </div>
      <div>
        <div style="margin-left: 72pt;"> (iii)&#160;&#160; To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
        <div> </div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0);"><font style="font-style: italic;">provided, however, </font>that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by
          those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
          relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;"> <br>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
      </div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report
            pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration
            statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
            controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and
            is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
            successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
            settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such
            issue.</font></div>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
            requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey on the 8th day of October, 2024.</font></div>
        <div><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z924d25b61f784c37a656d4bb50f4ec3c">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ACASTI PHARMA INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;"><u><font style="color: rgb(0, 0, 0);">/s/ </font>Prashant Kohli</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">Prashant Kohli</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
      <div>&#160;<br>
      </div>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">Each person whose signature appears below constitutes and appoints </font>Prashant Kohli<font style="color: rgb(0, 0, 0);"> his true and lawful
            attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration
            Statement and any and all related registration statements necessary to register additional securities, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto such attorney
            in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such
            attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div>
        <div>&#160;</div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated
          below.</div>
        <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfcb3761cf2e643d1a4d152eabb8edc60">

          <tr>
            <td nowrap="nowrap" style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 55%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 18%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center;"><font style="font-style: italic;">/s/</font>&#160;<font style="font-style: italic; color: rgb(0, 0, 0);">Prashant Kohli</font></div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">Chief Executive Officer and Director</td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Prashant Kohli</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 55%; vertical-align: top;">
              <div>(Principal Executive Officer)</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center;"><font style="font-style: italic;">/s/</font>&#160;<font style="font-style: italic;">Robert J. DelAversano</font></div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">
              <div>Principal Financial Officer</div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center;">Robert J. DelAversano</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 55%; vertical-align: top;">
              <div>(Principal Financial and Principal Accounting Officer)</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center;"><font style="font-style: italic;">/s/</font>&#160;<font style="font-style: italic; color: rgb(0, 0, 0);">Vimal Kavuru</font></div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div>Chair of the Board and Director</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Vimal Kavuru</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-style: italic;">/s/ Brian Davis</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div>Director</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center;">Brian Davis</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center;"><font style="font-style: italic;">/s/</font>&#160;<font style="font-style: italic;">George Kottayil</font></div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div>Director</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center;">George Kottayil</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 55%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 25%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-style: italic;">/s/ Edward Neugeboren</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 55%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div>Director</div>
              </div>
            </td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" rowspan="2" style="width: 18%; vertical-align: middle; padding-bottom: 2px;">
              <div>
                <div style="text-align: center;">October 8, 2024</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: center;">Edward Neugeboren</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ef20036399_s8.htm", "description": "S-8", "secsgml_size_bytes": 72806}]
{"company-data": {"conformed-name": "Acasti Pharma Inc.", "cik": "0001444192", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-282537", "film-number": "241359184"}, "business-address": {"street1": "103 CARNEGIE CENTER", "street2": "SUITE 300", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "609-322-1602"}, "mail-address": {"street1": "103 CARNEGIE CENTER", "street2": "SUITE 300", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
As filed with the Securities and Exchange Commission on October 8, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ACASTI PHARMA INC.
(Exact name of Registrant as specified in its charter)
Delaware
98-1359336
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
103 Carnegie Center, Suite 300
Princeton, New Jersey
08540
(Address of Principal Executive Offices)
(Zip Code)
ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN
(Full title of the plan)
Prashant Kohli
Chief Executive Officer
Acasti Pharma Inc.
103 Carnegie Center, Suite 300
Princeton, New Jersey 08540
(Name and Address of Agent for Service)
(609) 322-1602
(Telephone Number, Including Area Code, of Agent For Service)
Copy to:
Steven J. Abrams
Hogan Lovells US LLP
1735 Market Street, 23rd Floor
Philadelphia, PA 19103
(267) 675-4600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large
        accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act.  ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
This Registration Statement (the "Registration Statement") on Form S-8 is being filed with the Securities and Exchange Commission (the "Commission") for the purpose of registering the offer and
        issuance of shares of common stock, par value $0.0001 per share (the "Common Stock") of Acasti Pharma Inc. (the "Registrant," or the "Company") to certain directors, employees and consultants of the Company and/or its subsidiaries under the
        Company's 2024 Equity Incentive Plan (as it may be amended from time to time, the "2024 Equity Incentive Plan").
Pursuant to Part I of Form S-8, the information specified under Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428
        under the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to participants in the 2024 Equity
        Incentive Plan as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, when taken together, constitute a
        prospectus that meets the requirements of Section 10(a) of the Securities Act. Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as a prospectus or prospectus supplement
        pursuant to Rule 424 under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents filed by the Company with the Commission are incorporated by reference herein:
(a)
The Company's Annual Report on Form 10-K for the year ended March 31, 2024, filed with the Commission on
June 21, 2024
;
(b)
The Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Commission on
August 9,
                    2024
;
(c)
The Company's Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports
                      that relate to such items), filed with the Commission on
June 27, 2024
,
August 16, 2024
,
September 25, 2024
,
September 30, 2024
and
October 7, 2024
; and
(d)
The description of the Company's common stock included in the final prospectus dated August 7, 2024, filed with the Commission on
August 7, 2024
pursuant to Rule 424(b)(3).
All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the
        "Exchange Act"), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference
        herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are "furnished" rather than filed with the Commission; provided, however, that documents or portions thereof
        that are furnished and not filed in accordance with the rules of  the Commission shall not be deemed to be incorporated by reference herein.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement
        contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so
        modified or superseded, to constitute a part hereof.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Set forth below is a description of the General Corporation Law of the State of Delaware (the "DGCL"), the Company's Certificate of Incorporation and the Company's Bylaws, as
        such provisions relate to the indemnification of the Company's directors and officers. This description is intended only as a summary and is qualified in its entirety by reference to the DGCL, the Company's Certificate of Incorporation and the
        Company's Bylaws.
Section 102(b)(7) of the DGCL generally permits a Delaware corporation to provide in its certificate of incorporation that directors or certain officers of the corporation
        shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) with respect to directors and officers, any breach of the director's or
        officer's duty of loyalty to the corporation or its stockholders; (ii) with respect to directors and officers, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) with respect to
        directors, payments of unlawful dividends or unlawful stock repurchases or redemptions under Section 174 of the DGCL; (iv) with respect to directors and officers, any transaction from which the director or officer derived an improper personal
        benefit; or (v) with respect to officers, any action by or in the right of the corporation.
Section 145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any
        threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent
        of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys' fees), judgments, fines and
        amounts paid in settlement actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner he or she reasonably believed was in or not opposed to the corporation's best
        interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
Section 145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any
        threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
        the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or
        settlement of such action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation's best interests, except that no indemnification shall be permitted without judicial
        approval if a court has determined that the person is to be liable to the corporation with respect to such claim.
Section 145(c) of the DGCL provides that, if a present or former director or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the
        DGCL, the corporation must indemnify such officer or director against the expenses (including attorneys' fees) he or she actually and reasonably incurred in connection with such action.
Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or
        agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any such
        capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability under Section 145 of the DGCL.
The Company's Certificate of Incorporation contains provisions that limit the liability of the Company's directors and officers for monetary damages to the fullest extent
          permitted by the DGCL. In addition, if the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Company's directors and officers will be further limited to
          the greatest extent permitted by the DGCL.
The Company's Bylaws provide that the Company will indemnify its directors and officers, and may indemnify its employees, agents and any other persons, to the fullest extent
          permitted by the DGCL, subject to limited exceptions. The Company's Bylaws also provide that the Company must advance expenses incurred by or on behalf of a current or former director or officer in advance of the final disposition of any action
          or proceeding, subject to limited exceptions.
Further, the Company has entered into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification
          provisions contained in the DGCL. These indemnification agreements require the Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These
          indemnification agreements also require the Company to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. The Company believes that
          these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.
Directors' and officers' liability insurance has been purchased for the benefit of the Company's directors and officers to back up the Company's indemnification of them
          against liability incurred in their capacity as directors and officers, subject to certain limitations under applicable law. The Company also maintains insurance policies under which its directors and officers are insured, within the limits and
          subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are parties by reason of being
          or having been directors or officers of the Company. The coverage provided by these policies may apply whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
Exhibit
Number
Description of Document
3.1
Certificate of Incorporation of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed with the Commission on October 7, 2024)
3.2
Bylaws of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.4 to the Company's Current Report on Form 8-K filed with the Commission on October 7, 2024)
4.1
Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Commission on October 7, 2024)
5.1*
Opinion of Hogan Lovells US LLP
10.1
Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Commission on September 30, 2024)
10.3
Form of 2024 Incentive Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company's Registration Statement on Form S-4 filed with the Commission
                  on June 27, 2024)
10.4
Form of 2024 Non-Qualified Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Company's Registration Statement on Form S-4 filed with the
                  Commission on June 27, 2024)
23.1*
Consent of KPMG LLP, independent registered public accounting firm
23.2*
Consent of Ernst & Young LLP, independent registered public accounting firm
23.3*
Consent of Hogan Lovells US LLP (included in Exhibit 5.1)
24.1*
Power of Attorney (included on signature page hereto)
107*
Filing Fee Table
*
Filed herewith
Item 9.
Undertakings.
(a)
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to the registration statement:
(i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
            aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
            not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
            changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee Table", as applicable, in the effective
            registration statement;
(iii)   To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however,
that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by
          those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
          relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)
That, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report
            pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration
            statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
            controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and
            is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
            successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
            settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such
            issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
            requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey on the 8th day of October, 2024.
ACASTI PHARMA INC.
By:
/s/
Prashant Kohli
Name:
Prashant Kohli
Title:
Chief Executive Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints
Prashant Kohli
his true and lawful
            attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration
            Statement and any and all related registration statements necessary to register additional securities, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto such attorney
            in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such
            attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated
          below.
Name
Title
Date
/s/
Prashant Kohli
Chief Executive Officer and Director
October 8, 2024
Prashant Kohli
(Principal Executive Officer)
/s/
Robert J. DelAversano
Principal Financial Officer
October 8, 2024
Robert J. DelAversano
(Principal Financial and Principal Accounting Officer)
/s/
Vimal Kavuru
Chair of the Board and Director
October 8, 2024
Vimal Kavuru
/s/ Brian Davis
Director
October 8, 2024
Brian Davis
/s/
George Kottayil
Director
October 8, 2024
George Kottayil
/s/ Edward Neugeboren
Director
October 8, 2024
Edward Neugeboren